 "India's shortage of remdesivir is easing, says producer Cipla")
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital Covid-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
Remdesivir, made by US-based Gilead Sciences Inc, has been in high demand globally, and a handful of companies including Cipla are authorised to make and sell generic versions in 127 developing nations.
Cipla's launch of remdesivir in late June, along with subsequent launches by others, has helped ease supply bottlenecks in India, Cipla's Global Chief Financial Officer, Kedar Upadhye, told Reuters.
"Of late, some of the
